ALEX Lab narxALEX

Alex was an ambitious investor with an eye for emerging cryptocurrencies. When Alex first heard about Treat Coin, it was positioned as a revolutionary token with strong use cases in decentralized finance (DeFi) and gaming. It was designed to reward users for engagement, similar to how Ethereum powers DeFi protocols or how Dogecoin gained traction through its vibrant community. Initially, Alex struggled with the big question: Should I hold Treat Coin for the long haul or trade it actively to maximize profits? The Temptation to Trade In the early days, $TREAT Coin’s value was volatile. The price surged 50% one day due to a partnership announcement and dropped 30% the next after a market correction. Alex saw this volatility as an opportunity. By trading Treat Coin actively, Alex aimed to profit from these short-term swings. At first, the strategy worked. Alex made decent profits by buying during dips and selling during spikes. But over time, it became clear that the constant trading came with its downsides: High transaction fees on the blockchain ate into profits. The stress of tracking prices daily became overwhelming. A few bad trades led to significant losses, erasing earlier gains. The Case for Holding Frustrated, Alex started researching other successful coins. Ethereum’s meteoric rise stood out. Early investors who believed in Ethereum’s potential held their tokens through market cycles and reaped massive rewards when its ecosystem flourished. Similarly, Solana, with its focus on speed and scalability, rewarded holders as developers adopted it for innovative projects. Alex realized that Treat Coin had a strong roadmap, a growing community, and unique utility. By holding, Alex could benefit from: Long-term growth as Treat Coin’s use cases expanded. Staking rewards offered by the platform, which compounded Alex’s holdings. Avoiding the emotional rollercoaster of trading. The Outcome Alex decided to adopt a hybrid approach. While holding the majority of Treat Coins to benefit from long-term growth, Alex kept a small portion for trading during significant market movements. This balanced strategy allowed Alex to participate in Treat Coin’s success without succumbing to the pitfalls of overtrading. Today, Treat Coin has grown into a recognized player in the crypto space, rewarding holders who believed in its potential, just like Ethereum and Solana did. Alex’s story is a reminder that whether you hold or trade, understanding the fundamentals of a coin and aligning your strategy with your goals is the key to success.

Alex Shevchenko, CEO of Aurora Labs said: $AURORA “With Aurora Cloud Console, launching a chain is now easier, faster and completely accessible. In just days, you can have a fully customizable chain powered by NEAR’s robust network. We’ve removed the complexity, so builders can focus on creating great products while tapping into a thriving ecosystem of liquidity, tools, and users. Aurora Cloud Console is the gateway to Web3.”

According to crypto analyst Alex Clay, XRP is breaking out of a symmetrical triangle that is has been consolidating with for 2275 days. #XRP/USDT$XRP is breaking out of the symmetrical triangle (2275 Days we were accumulating inside the one and fighting with SEC)🧐 I am bullish🚀 Mid-Term Target – 1.2580$ Mid-Term Target – 1.5700$ Long-Term Target – 3.1000$ pic.twitter.com/n6947GILxC — Alex Clay (@cryptclay) July 22, 2024 His mid-term targets are $1.2580 and $1.57, whilst his longer-term target is $3.10. That would mark a more than 5x return for the XRP price from current levels. Not bad. And Alex Clay isn’t the only bullish analyst that has spotted the potential bullish breakout. X users XRP Captain and The Moon also tweet about a potential triangle pattern breakout.$CLAY

The TON blockchain is setting its sights on expanding into the United States, banking on a potential shift in the regulatory landscape under Donald Trump’s leadership. The project, originally founded by Telegram, is optimistic that a Trump administration could bring a more favorable environment for blockchain and cryptocurrency development in the country. Crypto enthusiasts and industry insiders, like Alex Royce, have noted that Trump’s previous stance on deregulation and fostering innovation might align with the blockchain industry’s needs. During his earlier presidency, Trump’s administration showed interest in reducing regulatory hurdles for emerging technologies, which some believe could pave the way for a more open dialogue between blockchain projects and policymakers. The TON blockchain, with its roots in fast and scalable decentralized technology, sees the US as a significant market for adoption. However, like many crypto projects, it has faced challenges navigating the often ambiguous and stringent regulations currently in place. Expanding into the US under a more lenient and blockchain-friendly administration could help TON achieve broader adoption and facilitate partnerships with American enterprises. While it's still speculative whether Trump’s leadership will bring about these hoped-for changes, the prospect of a regulatory shift has sparked excitement in the crypto community. If the US can strike a balance between oversight and innovation, it could position itself as a global leader in blockchain technology, something projects like TON are eager to capitalize on. For now, all eyes are on the evolving political and regulatory landscape, as blockchain innovators like TON prepare for what could be a transformative period for the industry.$TON

Genetic Engineering & Biotechnology News Home Topics Artificial Intelligence AI, Cell/Gene Therapy, Precision Medicine Drive Bullish Biotech Investment Survey of investors shows continued optimism for life sciences despite VC declines, antitrust and IP concerns By Alex Philippidis June 22, 2023 Credit: whyframestudio/Getty Images While life sciences investment has retreated from its all-time highs during the COVID-19 pandemic, investors surveyed by a national business law firm are still bullish about the sector based on the growth potential seen in artificial intelligence (AI), cell and gene therapy (CGT), and other new technologies. According to the 2023 Investment Funds Outlook Report issued recently by Barnes & Thornburg, more than one-third (36%) of 125 people surveyed included the life sciences as among areas of current investment or focus. Of those life-sci investors, 29% said they plan to invest an average of between $6 million and $10 million in a life sciences fund, while 28% said they will invest an average $1 million to $5 million. Encouragingly, 18% of investors plan to invest more than $25 million on average, and 16% between $11 million and $25 million—though the remaining 9% said they will only invest less than $1 million. The 125 investors consisted of limited partners, sponsors, and service providers who were surveyed in February with help from market data services provider Dynata. Survey respondents hailed from 29 U.S. states and represented hedge fund, private equity, credit, and venture capital organizations across the life sciences and more than a dozen other industries. The life sciences investors told Barnes & Thornburg they will continue to pour as much capital into their life-sci funds as they did before the financial markets turned bearish two years ago. That bearishness is reflected in declines for most biotech stocks as well as the 37% year-to-year decline in the total value of U.S. and European VC deals reported by EY, to $16.88 billion in 2022 from $26.62 billion in 2021. PitchBook data reported by commercial real estate firm Cushman & Wakefield a 28% year-over-year decline in U.S. life-sci venture investment, to $35.8 billion from $49.2 billion. VCs, vaccines, and value During Q1 2023, EY reported a total $2.381 billion in venture capital was invested in biotech companies, down 72% from the $8.541 billion invested a year earlier, and lower than any quarter of 2022. The VC decline is of particular concern since the market downturn has impeded companies from raising greater sums of capital (and investors from cashing in on or “exiting” their investments) by going public, whether by completing initial public offerings (IPOs) or by forming special purpose acquisition companies (SPACs). According to EY data, total biotech IPO value generated in Q1 2023 was $280 million, down 18% from $342 million in the year-ago quarter.